Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our specialist services

Adaptive Phase I & II
Adaptive Phase III
TQT Studies
Bridging Studies
Patient Recruitment
Data Management
Gene Editing & Gene Silencing
Regulatory Strategy Services
Pharmacovigilance

サービス一覧

適応的第I相・第II相試験
適応的第III相試験
TQT試験（心電図QT間隔評価試験）
ブリッジング試験
被験者リクルートメント
データマネジメント
遺伝子編集・遺伝子サイレンシング
規制戦略サービス
ファーマコビジランス
YOU ARE HERE: HOME > NEWS

Patient with rare bleeding disorder becomes first to test new treatment

22
May 2024

The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.

View Article

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

30
April 2024

Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.

View Article

Announcement of Jorg Becoming President Elect

22
April 2024

Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.

View Article

Single-dose gene silencing cure for fatal heart disease comes one step closer

20
March 2024

Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis

View Article

Ensuring The Future Of The Experienced Investigator Is Ingrained In Good Clinical Practice Guidance

3
January 2024

The ICH Expert Working Group has been revising the Good Clinical Practice (GCP) guideline, ICH E6 (GCP) R3.

View Article

Powering STEM Dreams: Snowsfield's Exciting Tour of Richmond Pharmacology

18
December 2023

Richmond Pharmacology recently welcomed STEM leaders from Snowsfield Primary School, marking a follow-up to our donation of STEM books for their library.

View Article

Meet the experts

Meet the leadership team and scientific experts behind Richmond Pharmacology's clinical research excellence.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event
© 2026 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesRejectAccept